NASDAQ:AGIO - Agios Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$57.04 -1.64 (-2.79 %)
(As of 04/24/2019 01:55 PM ET)
Previous Close$58.68
Today's Range$56.93 - $58.27
52-Week Range$41.63 - $99.82
Volume5,750 shs
Average Volume459,950 shs
Market Capitalization$3.33 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.38
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology for the treatment of cancer and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Receive AGIO News and Ratings via Email

Sign-up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AGIO
CUSIPN/A
Phone617-649-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$94.39 million
Book Value$11.82 per share

Profitability

Net Income$-346,020,000.00
Net Margins-366.61%

Miscellaneous

Employees482
Market Cap$3.33 billion
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable

Agios Pharmaceuticals (NASDAQ:AGIO) Frequently Asked Questions

What is Agios Pharmaceuticals' stock symbol?

Agios Pharmaceuticals trades on the NASDAQ under the ticker symbol "AGIO."

How were Agios Pharmaceuticals' earnings last quarter?

Agios Pharmaceuticals Inc (NASDAQ:AGIO) issued its quarterly earnings data on Thursday, February, 14th. The biopharmaceutical company reported ($1.58) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.65) by $0.07. The biopharmaceutical company earned $30 million during the quarter, compared to the consensus estimate of $19.98 million. Agios Pharmaceuticals had a negative net margin of 366.61% and a negative return on equity of 44.13%. The firm's revenue was up 200.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.81) EPS. View Agios Pharmaceuticals' Earnings History.

When is Agios Pharmaceuticals' next earnings date?

Agios Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, May 3rd 2019. View Earnings Estimates for Agios Pharmaceuticals.

What price target have analysts set for AGIO?

11 Wall Street analysts have issued 12-month price targets for Agios Pharmaceuticals' shares. Their forecasts range from $80.00 to $123.00. On average, they expect Agios Pharmaceuticals' share price to reach $97.8571 in the next year. This suggests a possible upside of 71.6% from the stock's current price. View Analyst Price Targets for Agios Pharmaceuticals.

What is the consensus analysts' recommendation for Agios Pharmaceuticals?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Agios Pharmaceuticals in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Agios Pharmaceuticals.

What are Wall Street analysts saying about Agios Pharmaceuticals stock?

Here are some recent quotes from research analysts about Agios Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Agios depends heavily on Celgene for revenues, which it earns in the form of collaboration revenues and royalty revenues on Idhifa sales. Stiff competition from large pharmaceutical companies including AstraZeneca, Bayer, Eli Lilly, Roche, GlaxoSmithKline, Merck, Pfizer and Sanofi is another matter of concern for the company. Shares of the company have underperformed the industry in 2018. Nevertheless, Agios' first wholly owned precision medicine, Tibsovo, was approved by the FDA for treating AML. The drug has generated strong sales in the very first quarter following its FDA nod. The company is also focused on expanding the label for Tibsovo to advance its cancer and rare genetic disease clinical development programs.Loss estimates have widened slighty ahead of the Q4 earnings release. Agios has a mixed record of earnings surprises in recent quarters. " (2/12/2019)
  • 2. Canaccord Genuity analysts commented, "We maintain a favorable view on Fouse as the CEO given her expensive experience at Laboratories, holding various senior roles focusing on corporate strategies, finance, and operations. We believe Fouse will help maintain AGIO’s heading in launching the approved products and developing the pipeline." (9/5/2018)
  • 3. Needham & Company LLC analysts commented, "BeiGene announced the pricing of its Hong Kong initial public offering of 65,600,000 ordinary shares. Based on the assumed exchange rate, the public offering, priced at $13.76 (HK$108) per share or $178.9 per American Depositary Share (ADS) is expected to raise ~$903M (HK$7.08bn)." (8/2/2018)

Has Agios Pharmaceuticals been receiving favorable news coverage?

Media headlines about AGIO stock have trended very positive on Wednesday, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Agios Pharmaceuticals earned a news impact score of 3.3 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future.

Who are some of Agios Pharmaceuticals' key competitors?

What other stocks do shareholders of Agios Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Agios Pharmaceuticals investors own include Celgene (CELG), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Netflix (NFLX), Sarepta Therapeutics (SRPT), Tesla (TSLA), Alibaba Group (BABA), Biogen (BIIB), Micron Technology (MU) and bluebird bio (BLUE).

Who are Agios Pharmaceuticals' key executives?

Agios Pharmaceuticals' management team includes the folowing people:
  • Dr. David P. Schenkein, Pres & Exec. Chairman (Age 62)
  • Dr. Jacqualyn A. Fouse, CEO & Director (Age 58)
  • Dr. Lewis Clayton Cantley, Co-Founder & Member of Scientific Advisory Board (Age 70)
  • Mr. Andrew Hirsch, CFO & Head of Corp. Devel. (Age 48)
  • Dr. Scott A. Biller Ph.D., Chief Scientific Officer (Age 63)

Who are Agios Pharmaceuticals' major shareholders?

Agios Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.01%) and Virtu Financial LLC (0.01%). Company insiders that own Agios Pharmaceuticals stock include Carman Alenson, Celgene European Investment Co, Christopher Bowden, Corp /De/ Celgene, David P Schenkein, David Scadden, John Maraganore, Kaye I Foster-Cheek, Lewis Clayton Jr Cantley, Scott Biller and Steven L Hoerter. View Institutional Ownership Trends for Agios Pharmaceuticals.

Which major investors are selling Agios Pharmaceuticals stock?

AGIO stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Agios Pharmaceuticals company stock in the last year include Carman Alenson, Christopher Bowden, David P Schenkein, John Maraganore, Kaye I Foster-Cheek, Scott Biller and Steven L Hoerter. View Insider Buying and Selling for Agios Pharmaceuticals.

Which major investors are buying Agios Pharmaceuticals stock?

AGIO stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Agios Pharmaceuticals stock in the last two years include Celgene European Investment Co, Corp /De/ Celgene and David Scadden. View Insider Buying and Selling for Agios Pharmaceuticals.

How do I buy shares of Agios Pharmaceuticals?

Shares of AGIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agios Pharmaceuticals' stock price today?

One share of AGIO stock can currently be purchased for approximately $57.04.

How big of a company is Agios Pharmaceuticals?

Agios Pharmaceuticals has a market capitalization of $3.33 billion and generates $94.39 million in revenue each year. The biopharmaceutical company earns $-346,020,000.00 in net income (profit) each year or ($6.03) on an earnings per share basis. Agios Pharmaceuticals employs 482 workers across the globe.

What is Agios Pharmaceuticals' official website?

The official website for Agios Pharmaceuticals is http://www.agios.com.

How can I contact Agios Pharmaceuticals?

Agios Pharmaceuticals' mailing address is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-8600 or via email at [email protected]


MarketBeat Community Rating for Agios Pharmaceuticals (NASDAQ AGIO)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  348 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  653
MarketBeat's community ratings are surveys of what our community members think about Agios Pharmaceuticals and other stocks. Vote "Outperform" if you believe AGIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGIO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/24/2019 by MarketBeat.com Staff

Featured Article: Catch-Up Contributions

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel